Verrica Pharmaceuticals Inc

NASDAQ: VRCA
$7.84
+$0.23 (+3.0%)
Closing price May 9, 2024

VRCA Chart and Intraday Price

VRCA Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER, PA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 233.46M USD
Shares Outstanding 42,064,600
Verrica Pharmaceuticals Inc is a pioneering dermatology-focused biopharmaceutical company. It specializes in developing innovative treatments for skin diseases, including common and genital warts, basal cell carcinoma, and plantar warts. Its leading product, YCANTH (VP-102), is making strides in phase III trials for common warts and has shown promise in other skin conditions. The company also explores cancer treatments with VP-315 and targets plantar warts with VP-103. Founded in 2013 and based in West Chester, Pennsylvania, Verrica Pharmaceuticals is committed to advancing dermatological care worldwide.

VRCA Articles

Here's What Insiders Are Buying to Wrap Up the Year
As the year wound to a close, the most notable insider buying was focused on biotech stocks, but an oil and gas company CEO also returned to the buy window.
Trey Thoelcke
Published:

Buffett, Dollar Tree Purchases Highlight Pre-Christmas Insider Buying
Warren Buffett's Berkshire Hathaway has again bolstered its stake in Occidental Petroleum, and action at Dollar Tree also highlights recent insider buying.
Trey Thoelcke
Published: